Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original). A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor.

Claim 2 (original). The method of claim 1 wherein the mammal is a human.

Claim 3 (original). The method of claim 1 wherein the mammal is a non-human mammal.

Claim 4 (original). The method of claim 1 wherein the Src family tyrosine kinase inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.

Claim 5 (withdrawn). The method of claim 1 wherein the Src family tyrosine kinase inhibitor is a pyrazolopyrimidine selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl) pyrazolo[3,4-*d*]pyrimidine, and a mixture thereof.

Claim 6 (withdrawn). The method of claim 1 wherein the Src family tyrosine kinase inhibitor is a macrocyclic dienone selected from the group consisting of Geldanamycin, Herbimycin A, Radicicol R2146, and a mixture thereof.

Claim 7 (withdrawn). The method of claim 1 wherein the Src family tyrosine kinase inhibitor is 6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylphenylamino)-8*H*-pyrido[2,3-*d*]pyrimidine-7-one.

Claim 8 (original). The method of claim 1 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile.

Claim 9 (original). The method of claim 8 wherein the 4-anilino-3-quinolinecarbonitrile has the general Formula (I):

(I)



wherein R^1 is methyl or $-(CH_2)_n-Z$; X^1 is F, Cl, Br, I, and methyl; X^2 is H, F, Cl, Br, I, and methyl; X^3 is H or methoxy; n is 2, 3, 4, or 5; and Z is 4-morpholinyl, 4-(1-methylpiperzinyl), 4-(1-ethylpiperzinyl), 4-(1-propylpiperzinyl), 1-(*cis*-3, 4, 5-trimethylpiperzinyl), 1-piperazinyl, 1-(4-methylhomopiperazinyl), 1-piperidinyl, 4-(1-hydroxypiperidinyl), 2-(1,2,3-triazolyl), 1-(1,2,3-triazolyl), 1-imidazolyl, $-NHCH_2CH_2$-1-morpholinyl, and $-N(CH_3)-CH_2CH_2-N(CH_3)_2$.

Claim 10 (original). The method of claim 9 wherein R^1 is $-(CH_2)_n-Z$, wherein X^1 and X^2 are both chloro, X^3 is methoxy, n is 3 and Z is 4-morpholinyl.

Claim 11 (currently amended). The method of claim 8 wherein the 4-anilino-3-quinolinecarbonitrile is ~~4-anilino-3-quinolinecarbonitrile is~~ 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile.

Claim 12 (original). The method of claim 8 wherein the 4-anilino-3-quinolinecarbonitrile is 4-[(2,4-dichlorophenyl)amino]-6-methoxy-7-[3-(morpholin-4-yl)propoxy]-3-quinolinecarbonitrile (SKI-606).

Claim 13 (original). The method of claim 1 wherein the pharmaceutical composition is administered to the mammal by intraperitoneal injection.

Claim 14 (original). The method of claim 1 wherein the pharmaceutical composition is administered to the mammal by intravenous injection.

Claim 15 (original). The method of claim 1 wherein the pharmaceutical composition is administered to the mammal within about 6 hours after the myocardial infarction.

Claim 16 (original). The method of claim 1 wherein the pharmaceutical composition is administered to the mammal within about 24 hours after the myocardial infarction.

Claim 17 (original). A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising an ATP-competitive Src family tyrosine kinase inhibitor having a hydrophobic group that is less than about 6 angstroms in size situated adjacent to an ATP-mimicing heteroaromatic moiety.

Claim 18 (withdrawn). The method of claim 17 wherein the ATP-competitive Src family tyrosine kinase inhibitor is a 5-(4-methylphenyl) substituted pyrazolo[3,4-*d*] pyrimidine compound.

Claim 19 (withdrawn). The method of claim 17 wherein the ATP-competitive Src family tyrosine kinase inhibitor is a 5-(4-halophenyl) substituted pyrazolo[3,4-*d*] pyrimidine compound.

Claim 20 (currently amended). The method of claim 17 wherein the ~~pyrazolopyrimidine class~~ ATP-competitive Src family tyrosine kinase inhibitor is a 4-(4-haloanilino)-3-quinolinecarbonitrile compound.

Claims 21-29 (cancelled).

Claim 30 (original). A method for prophylactic treatment of a mammal at risk of myocardial infarction, the method comprising administering to the mammal a prophylactic amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor.

Claim 31 (original). The method of claim 30 wherein the mammal is a non-human mammal.

Claim 32 (original). The method of claim 30 wherein the mammal is a human.

Claim 33 (original). The method of claim 30 wherein the pharmaceutical composition is orally administered to the mammal.

Claim 34 (original). The method of claim 30 wherein the pharmaceutical composition is parenterally administered to the mammal.

Claim 35 (original). The method of claim 30 wherein the chemical Src family tyrosine kinase inhibitor is selected from the group consisting of a pyrazolopyrimidine class

Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.

Claim 36 (withdrawn). The method of claim 30 wherein the chemical Src family tyrosine kinase inhibitor is a pyrazolopyrimidine selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*-] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*-] pyrimidine, and a mixture thereof.

Claim 37 (original). The method of claim 30 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile having the general Formula (I):

(I)



wherein R^1 is methyl or $-(CH_2)_n-Z$; X^1 is F, Cl, Br, I, and methyl; X^2 is H, F, Cl, Br, I, and methyl; X^3 is H or methoxy; n is 2, 3, 4, or 5; and Z is 4-morpholinyl, 4-(1-methylpiperzinyl), 4-(1-ethylpiperzinyl), 4-(1-propylpiperzinyl), 1-(*cis*-3, 4, 5-trimethylpiperzinyl), 1-piperazinyl, 1-(4-methylhomopiperazinyl), 1-piperidinyl, 4-(1-hydroxypiperidinyl), 2-(1,2,3-triazolyl), 1-(1,2,3-triazolyl), 1-imidazolyl, $-NHCH_2CH_2$-1-morpholinyl, and $-N(CH_3)-CH_2CH_2-N(CH_3)_2$.

Claim 38 (original). The method of claim 37 wherein R^1 is $-(CH_2)_n-Z$, wherein X^1 and X^2 are both chloro, X^3 is methoxy, n is 3 and Z is 4-morpholinyl.

Claim 39 (currently amended). The method of claim 30 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile selected from the group consisting of ~~4-anilino-3-quinolinecarbonitrile is 4-anilino-3-quinolinecarbonitrile is~~ 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile and 4-[(2,4-dichlorophenyl)amino]-6-methoxy-7-[3-(morpholin-4-yl)propoxy]-3-quinolinecarbonitrile (SKI-606).

Claim 40 (original). The method of claim 30 wherein the Src family tyrosine kinase inhibitor is an ATP-competitive Src family tyrosine kinase inhibitor having a hydrophobic group that is less than about 6 angstroms in size situated adjacent to an ATP-mimicing heteroaromatic moiety.